Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Induced Pluripotent Stem Cell (iPSC) Market Expansion From $4.02 Billion In 2026 To $5.74 Billion In 2030
The market for induced pluripotent stem cells (iPSCs) has experienced robust expansion, projecting a rise from $3.67 billion in 2025 to $4.02 billion by 2026, which reflects a compound annual growth rate of 9.5%. This upward trajectory during the preceding period was propelled by significant advancements in cellular reprogramming, a decrease in ethical debates surrounding embryonic stem cells, augmented investment in stem cell investigations, strengthened academic partnerships, and a growing incidence of chronic and degenerative health conditions.
The induced pluripotent stem cell (ipsc) sector is poised for considerable expansion over the upcoming years, projecting a market value of $5.75 billion by 2030, fueled by a compound annual growth rate (CAGR) of 9.3%. This projected growth trajectory is largely propelled by the broadening scope of regenerative medicine, a heightened demand for tailored therapeutic approaches, escalating investments in cell and gene therapies, and the increasing utilization of ipscs in the investigation of neurological and cardiac conditions, alongside supportive regulatory frameworks for cutting-edge treatments. Key developments anticipated during this forecast period encompass a greater deployment of ipscs for disease modeling, their augmented use in drug discovery and safety assessments, the expansion of services for creating patient-specific cell lines, a heightened emphasis on ethical substitutes for embryonic stem cells, and progress in enhancing reprogramming efficiency and cellular durability.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp
Induced Pluripotent Stem Cell (iPSC) Market Growth Momentum: Which Factors Are Influencing Demand?
The rising incidence of conditions affecting the nervous system is anticipated to be a significant driver for the expansion of the induced pluripotent stem cell market. Neurological disorders encompass a range of ailments impacting the brain, spinal cord, and peripheral nerves, with examples including acute spinal cord injury, Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS). These pluripotent stem cells are invaluable tools for dissecting disease pathways and facilitating drug discovery, thereby illuminating the origins of neurological ailments and assisting in the creation of restorative treatments for conditions like Parkinson’s and Alzheimer’s. For example, data released in October 2023 by the World Federation of Neurology (WFN), an international non-profit organization based in the UK, indicated that over 40% of the world’s population were affected by a neurological condition, with projections suggesting this burden could nearly double by 2050. Consequently, the escalating occurrence of neurological disorders is directly fueling the growth trajectory of the induced pluripotent stem cell market.
Induced Pluripotent Stem Cell (iPSC) Market Segmentation: How Is The Market Structured Across Key Categories?
The induced pluripotent stem cell (ipsc) market covered in this report is segmented –
1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
3) By End-User: Hospitals, Research Laboratories
Subsegments:
1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies
2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research
3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies
4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications
5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research
Induced Pluripotent Stem Cell (iPSC) Market Trends Reshaping Industry Growth
Major companies operating in the induced pluripotent stem cell (IPSC) market are collaborating to Advance iPSC Technology to enhance regenerative medicine applications, improve disease modeling, accelerate drug discovery, and develop personalized therapeutic solutions. Induced Pluripotent Stem Cell (iPSC) technology refers to the scientific process and methodologies used to reprogram adult somatic cells (such as skin or blood cells) back into a pluripotent state, making them capable of differentiating into any type of cell in the body. For instance, in April 2024, SCG Cell Therapy Pte Ltd, a Singapore-based biotechnology company, and the Agency for Science, Technology and Research, a Singapore-based Statutory board, launched joint laboratories aimed at advancing cellular immunotherapies. The initiative is supported by close to S$30 million, emphasizing Singapore’s commitment to advancing biotechnology and healthcare solutions. The collaboration aims to develop scalable manufacturing processes for GMP-grade iPSC products, addressing the challenges of translating laboratory innovations into clinically viable therapies.
Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape And Leading Companies
Major companies operating in the induced pluripotent stem cell (ipsc) market are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, Parexel, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart
Access The Complete Induced Pluripotent Stem Cell (iPSC) Market Report:
https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report
Induced Pluripotent Stem Cell (iPSC) Market Leading Geography: Which Region Generates The Most Revenue?
North Americawas the largest region in the induced pluripotent stem cell (IPSC) market in 2025. Western Europewas the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (ipsc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
